UNSPSC 51413201: Cinepazic acid

This classification denotes a vasodilating agent with the molecular formula C18H24N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OX0J88C7UX, chemically known as 4-(3,4,5-trimethoxycinnamoyl)-1-piperazineacetic acid. but generally known as cinepazic acid, which bears US NIH Compound Identifier 6443799. European Medicines Agency schedules Cinepazic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06292MIG.

UNSPSC 51413201 Cinepazic acid, a Commodity code, represents pharmaceutical and over-the-counter medication procurement by state and local governments, including fire rescue services, health agencies, and cooperative purchasing alliances. State and local buyers acquire medications through a mix of individual purchase orders and framework agreements with pharmaceutical manufacturers and wholesalers. The work encompasses sealed-bid purchases of specific medication line items with firm pricing, multi-state cooperative purchasing contracts for generic pharmaceuticals distributed through authorized wholesalers, and exploratory procurement for direct-to-manufacturer prescription programs. Issuing bodies include municipal fire departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and regional cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local facilities).

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with bids due April 8, 2026, requesting 370 units of Labetalol HCI, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine, and 1,020 units of Diltiazem with a nine-month minimum expiration requirement and estimated contract value of $40,000; the solicitation includes a 5 percent Small Local Business Enterprise bid discount. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products through MMCAP with a response deadline of March 26, 2026, requiring vendors to supply products through three authorized wholesalers with pricing evaluated at 75 percent weight and compliance certifications in Good Manufacturing Practices and Drug Supply Chain Security Act mandatory. Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription program capabilities before launching a formal procurement.